Ofatumumab and its role as immunotherapy in chronic lymphocytic leukemia

被引：17

作者：

Sandhu, Suneet ^{[1
,2
]}

Mulligan, Stephen P. ^{[1
,2
]}

机构：

[1] Royal N Shore Hosp, Dept Haematol, St Leonards, NSW 2065, Australia

[2] Univ Sydney, Kolling Inst, St Leonards, NSW, Australia

来源：

HAEMATOLOGICA | 2015年 / 100卷 / 04期

关键词：

OBINUTUZUMAB; FLUDARABINE; CD20;

D O I：

10.3324/haematol.2015.124107

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：411 / 415

页数：5

共 15 条

[1] Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia [J].

Byrd, J. C. ;

Brown, J. R. ;

O'Brien, S. ;

Barrientos, J. C. ;

Kay, N. E. ;

Reddy, N. M. ;

Coutre, S. ;

Tam, C. S. ;

Mulligan, S. P. ;

Jaeger, U. ;

Devereux, S. ;

Barr, P. M. ;

Furman, R. R. ;

Kipps, T. J. ;

Cymbalista, F. ;

Pocock, C. ;

Thornton, P. ;

Caligaris-Cappio, F. ;

Robak, T. ;

Delgado, J. ;

Schuster, S. J. ;

Montillo, M. ;

Schuh, A. ;

de Vos, S. ;

Gill, D. ;

Bloor, A. ;

Dearden, C. ;

Moreno, C. ;

Jones, J. J. ;

Chu, A. D. ;

Fardis, M. ;

McGreivy, J. ;

Clow, F. ;

James, D. F. ;

Hillmen, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) :213-223

[2] Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study [J].

Coiffier, Bertrand ;

Lepretre, Stephane ;

Pedersen, Lars Moller ;

Gadeberg, Ole ;

Fredriksen, Henrik ;

van Oers, Marinus H. J. ;

Wooldridge, James ;

Kloczko, Janusz ;

Holowiecki, Jerzy ;

Hellmann, Anrzej ;

Walewski, Jan ;

Flensburg, Mimi ;

Petersen, Jorgen ;

Robak, Tadeusz .

BLOOD, 2008, 111 (03) :1094-1100

[3] Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial [J].

Cortelezzi, A. ;

Sciume, M. ;

Liberati, A. M. ;

Vincenti, D. ;

Cuneo, A. ;

Reda, G. ;

Laurenti, L. ;

Zaja, F. ;

Marasca, R. ;

Chiarenza, A. ;

Gritti, G. ;

Orsucci, L. ;

Storti, S. ;

Angelucci, E. ;

Cascavilla, N. ;

Gobbi, M. ;

Mauro, F. R. ;

Morabito, F. ;

Fabris, S. ;

Piciocchi, A. ;

Vignetti, M. ;

Neri, A. ;

Rossi, D. ;

Giannarelli, D. ;

Guarini, A. ;

Foa, R. .

LEUKEMIA, 2014, 28 (03) :642-648

[4]

Costa L. J., 2014, LEUKEMIA LYMPHOMA, P1

[5] Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study [J].

Doubek, Michael ;

Brychtova, Yvona ;

Panovska, Anna ;

Sebejova, Ludmila ;

Stehlikova, Olga ;

Chovancova, Jana ;

Malcikova, Jitka ;

Smardova, Jana ;

Plevova, Karla ;

Volfova, Pavlina ;

Trbusek, Martin ;

Mraz, Marek ;

Bakesova, Denisa ;

Trizuljak, Jakub ;

Hadrabova, Marketa ;

Obrtlikova, Petra ;

Karban, Josef ;

Smolej, Lukas ;

Oltova, Alexandra ;

Jelinkova, Eva ;

Pospisilova, Sarka ;

Mayer, Jiri .

AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (05) :417-421

[6] Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study [J].

Goede, V. ;

Fischer, K. ;

Engelke, A. ;

Schlag, R. ;

Lepretre, S. ;

Montero, L. F. C. ;

Montillo, M. ;

Fegan, C. ;

Asikanius, E. ;

Humphrey, K. ;

Fingerle-Rowson, G. ;

Hallek, M. .

LEUKEMIA, 2015, 29 (07) :1602-1604

[7] Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions [J].

Goede, Valentin ;

Fischer, Kirsten ;

Busch, Raymonde ;

Engelke, Anja ;

Eichhorst, Barbara ;

Wendtner, Clemens M. ;

Chagorova, Tatiana ;

de la Serna, Javier ;

Dilhuydy, Marie-Sarah ;

Illmer, Thomas ;

Opat, Stephen ;

Owen, Carolyn J. ;

Samoylova, Olga ;

Kreuzer, Karl-Anton ;

Stilgenbauer, Stephan ;

Doehner, Hartmut ;

Langerak, Anton W. ;

Ritgen, Matthias ;

Kneba, Michael ;

Asikanius, Elina ;

Humphrey, Kathryn ;

Wenger, Michael ;

Hallek, Michael .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (12) :1101-1110

[8] Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial [J].

Hallek, M. ;

Fischer, K. ;

Fingerle-Rowson, G. ;

Fink, A. M. ;

Busch, R. ;

Mayer, J. ;

Hensel, M. ;

Hopfinger, G. ;

Hess, G. ;

von Gruenhagen, U. ;

Bergmann, M. ;

Catalano, J. ;

Zinzani, P. L. ;

Caligaris-Cappio, F. ;

Seymour, J. F. ;

Berrebi, A. ;

Jaeger, U. ;

Cazin, B. ;

Trneny, M. ;

Westermann, A. ;

Wendtner, C. M. ;

Eichhorst, B. F. ;

Staib, P. ;

Buehler, A. ;

Winkler, D. ;

Zenz, T. ;

Boettcher, S. ;

Ritgen, M. ;

Mendila, M. ;

Kneba, M. ;

Doehner, H. ;

Stilgenbauer, S. .

LANCET, 2010, 376 (9747) :1164-1174

[9]

Hillmen P, 2013, AM SOC HAEMATOLOGY O, V122, P1266

[10] Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia [J].

Moreno, Carol ;

Montillo, Marco ;

Panayiotidis, Panayiotis ;

Dimou, Maria ;

Bloor, Adrian ;

Dupuis, Jehan ;

Schuh, Anna ;

Norin, Stefan ;

Geisler, Christian ;

Hillmen, Peter ;

Doubek, Michael ;

Trneny, Marek ;

Obrtlikova, Petra ;

Laurenti, Luca ;

Stilgenbauer, Stephan ;

Smolej, Lukas ;

Ghia, Paolo ;

Cymbalista, Florence ;

Jaeger, Ulrich ;

Stamatopoulos, Kostas ;

Stavroyianni, Niki ;

Carrington, Patrick ;

Zouabi, Hamadi ;

Leblond, Veronique ;

Gomez-Garcia, Juan C. ;

Rubio, Martin ;

Marasca, Roberto ;

Musuraca, Gerardo ;

Rigacci, Luigi ;

Farina, Lucia ;

Paolini, Rossella ;

Pospisilova, Sarka ;

Kimby, Eva ;

Bradley, Colm ;

Montserrat, Emili .

HAEMATOLOGICA, 2015, 100 (04) :514-519

← 1 2 →